AstraZeneca Plc’s (AZN) cancer drug Arimidex more than halved the chance of at-risk women developing tumors when used preventively, according to a study published in The Lancet medical journal today. In a trial among almost 4,000 post-menopausal women at high risk of the disease, those who took Arimidex for five years were 53 percent less likely to develop breast cancer than those who received a placebo, researchers led by Jack Cuzick at Queen Mary University of London’s Centre for Cancer Prevention wrote in the article. The findings confirm those of a 2011 trial involving Pfizer Inc.’s (PFE:US) Aromasin and show that Arimidex, also known as anastrozole, should be preferred to an older and more toxic drug, tamoxifen, by regulators for women who are predisposed to developing breast cancer, Cuzick and colleagues said in a statement.
Help employers find you! Check out all the jobs and post your resume.
